Abstract:512 Background: Testicular germ cell tumors (tGCTs) are rare but are highly curable, resulting in a large cohort of long-term survivors. The primary aim of most follow-up programs after initial treatment is to detect recurrence, which emphasizes regular imaging and measurement of serum tumor markers. Most relapses occur in the first two years after treatment. However, many of these patients also experience survivorship issues beyond the two-year timepoint which are underrecognized in the clinical setting and underreported in clinical literature. Methods: We retrospectively reviewed clinical documentation across a cohort of tGCT patients in St Bartholomew’s Hospital who received adjuvant treatment (n=171), treatment for metastatic cancer (n=325) and those who underwent surveillance only (n=225) from 2011 and 2021. Only patients with a minimum follow-up of 5 years were included. Data was collected between Year 3 to Year 10 after initial treatment, ie only after two years of surveillance were completed. The frequency in which the following terminology/symptoms appeared in clinical documentation was recorded: relapse, endocrinology (a hormone problem including, but not included to hypogonadism/diabetes/thyroid dysfunction), lifestyle advice (eg weight management), blood pressure, cholesterol, psychology, fertility and other problems. Each reported issue was only recorded once per patient for this study. Results: Relapse rates were 0-0.75% annually (0% adjuvant, 0.7% metastatic, 0.75% surveillance). Total relapse rates beyond the two year time point, per group, were 0% in the adjuvant group, 5.8% in the metastatic group, and 6.0% in the surveillance group. Of the patient group who received treatment, significantly more reported endocrinological issues (7.0% average annually in the adjuvant group vs 4.2% metastatic vs 0.1% surveillance). Issues relating to blood pressure were equally reported (5.5% average annually in adjuvant vs 2.95% in metastatic vs 2.60% in surveillance) as were cholesterol (4.7% average annually in adjuvant vs 2.2% in metastatic vs 2.2% in surveillance). Fertility issues were more commonly reported in the group of patients who received treatment for metastatic cancer (2.4%) as opposed to those who received adjuvant treatment(0.5%) and surveillance only (0.7%). Conclusions: Relapse rates in our cohort of patients are low and consistent with previous studies. However, we highlight multiple survivorship issues for patients who have received treatment – particularly issues pertaining to endocrinological issues and fertility. These results suggest the need to incorporate monitoring of survivorship issues into our routine follow-up to improve patient experiences and outcomes. We suggest that a specialist clinic focused on long-term survivorship issues be established to better address the needs of this patient population.

A population-based validation of the IGCCCG Update Consortium for survival in metastatic non-seminoma testis cancer

Clinicopathological characteristics and survival outcomes for testicular choriocarcinoma and non-testicular choriocarcinoma: A SEER database analysis.

Survival of stage III non-seminoma testis cancer patients versus simulated controls, according to race/ethnicity

Primary retroperitoneal germ-cell tumours (pR-GCT): Evaluation of treatment outcomes of an international retrospective collaboration (PRIMERE study).

North American patterns of care in clinical stage I testicular cancer from SWOG S1823.

Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium

MP73-19 VALIDATION OF PRIMARY TUMOR SURGERY AS A PROGNOSTIC INDICATOR IN SEMINOMA PATIENTS WITH DISTANT METASTASIS AT DIAGNOSIS: A POPULATION-BASED STUDY

Survival differences in non-seminoma testis cancer patients according to race/ethnicity

Epidemiology and clinical trends of testicular cancer and secondary malignant tumors in a north Italian province.

Malignant ovarian and testicular germ cell tumors: Common characteristics but different prognoses

Clinical Characteristics and Outcomes of Patients with Primary Mediastinal Germ Cell Tumors: A Single-Center Experience.

Urological Second Malignant Neoplasms in Testicular Nonseminoma Survivors: a Population-Based Analysis

Long-term Relapse and Survival in Clinical Stage I Testicular Teratoma

Survivorship issues beyond 2 years after treatment in testicular germ cell tumors: Experience from a large centre in the United Kingdom.

Contemporary survival in metastatic bladder cancer patients: A population-based study

Update of Epidemiology, Survival and Initial Treatment in Patients with Gastrointestinal Stromal Tumour in the USA: a Retrospective Study Based on SEER Database.

Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis

Retrospective observational cohort study on innovation in oncology and progress in survival: How far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a single population?

A 20-Year Retrospective Analysis

Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database

Establishment and Validation of an Individualized Nomogram for Survival Prediction of Primary Mediastinal Germ Cell Tumors Based on the SEER Database.